Instil Bio (TIL) Preferred Stock Liabilities (2020)
Instil Bio (TIL) posted quarterly Preferred Stock Liabilities of $332.0 million for Q4 2020, up 66.68% quarter-over-quarter from $199.2 million in Q3 2020.
Instil Bio (TIL) Preferred Stock Liabilities (2020) Analysis & Trends
Instil Bio's Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $332.0 million for Q4 2020.
- In Q4 2020, Preferred Stock Liabilities changed N/A year-over-year to $332.0 million; the TTM figure through Dec 2020 stood at $332.0 million (changed N/A YoY), while the FY2020 annual figure was $332.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q4 2020 stood at $332.0 million, up from $199.2 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $332.0 million in Q4 2020, with the low at $14.9 million in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Instil Bio | 51.68 Mn | 51.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 331.97 Mn |
| Sep 30, 2020 | 199.16 Mn |
| Jun 30, 2020 | 199.14 Mn |
| Mar 31, 2020 | 14.95 Mn |